Saturday, December 21, 2024 3:40:58 PM
Usually best to heed SEC warnings... like this one:
"Outcomes of Investing in OTC Stocks"
"This paper analyzes three aspects of over-the-counter (OTC) stocks: (1) the recent trends in the OTC stock market structure and size; (2) the documented properties of OTC stocks; and (3) the differences in returns based on investor and stock characteristics. Approximately 10,000 OTC stocks were quoted at the end of 2013 through 2015, generating a total trading volume of over $200 billion per year. Dollar volume has grown substantially since 2012 and is now concentrated in the segment of the OTC market with no requirements of registration or reporting to the U.S. Securities and Exchange Commission (SEC).
A synthesis of recent academic literature reveals troubling properties of OTC stocks. Academic studies find that OTC stocks tend to be highly illiquid; are frequent targets of alleged market manipulation; generate negative and volatile investment returns on average; and rarely grow into a large company or transition to listing on a stock exchange. Moreover, these properties tend to worsen when the OTC company has fewer disclosure-related eligibility requirements. I examine the relationship between OTC investor demographics and investment outcomes using a proprietary database of transaction-level OTC data with confidential investor information.
Analysis of 1.8 million trades by over 200,000 individual investors confirms that the typical OTC investment return is severely negative. Investor outcomes worsen for OTC stocks that experience a promotional campaign or have weaker disclosure-related eligibility requirements. Demographic analysis reveals that older, retired, low-income, and less educated investors experience significantly poorer outcomes in OTC stock markets. Given that retail investors are the predominant owners of OTC stocks, and the documented trend towards less transparent OTC companies, the results of this study have important implications for investor protection."
https://www.sec.gov/about/divisions-offices/division-economic-risk-analysis/staff-papers-analyses/16dec16_white_outcomes-investing-otc-stocks
"Outcomes of Investing in OTC Stocks"
"This paper analyzes three aspects of over-the-counter (OTC) stocks: (1) the recent trends in the OTC stock market structure and size; (2) the documented properties of OTC stocks; and (3) the differences in returns based on investor and stock characteristics. Approximately 10,000 OTC stocks were quoted at the end of 2013 through 2015, generating a total trading volume of over $200 billion per year. Dollar volume has grown substantially since 2012 and is now concentrated in the segment of the OTC market with no requirements of registration or reporting to the U.S. Securities and Exchange Commission (SEC).
A synthesis of recent academic literature reveals troubling properties of OTC stocks. Academic studies find that OTC stocks tend to be highly illiquid; are frequent targets of alleged market manipulation; generate negative and volatile investment returns on average; and rarely grow into a large company or transition to listing on a stock exchange. Moreover, these properties tend to worsen when the OTC company has fewer disclosure-related eligibility requirements. I examine the relationship between OTC investor demographics and investment outcomes using a proprietary database of transaction-level OTC data with confidential investor information.
Analysis of 1.8 million trades by over 200,000 individual investors confirms that the typical OTC investment return is severely negative. Investor outcomes worsen for OTC stocks that experience a promotional campaign or have weaker disclosure-related eligibility requirements. Demographic analysis reveals that older, retired, low-income, and less educated investors experience significantly poorer outcomes in OTC stock markets. Given that retail investors are the predominant owners of OTC stocks, and the documented trend towards less transparent OTC companies, the results of this study have important implications for investor protection."
https://www.sec.gov/about/divisions-offices/division-economic-risk-analysis/staff-papers-analyses/16dec16_white_outcomes-investing-otc-stocks
Recent MRKR News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/20/2026 08:08:49 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/20/2026 08:07:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/20/2026 08:05:49 PM
- Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results • GlobeNewswire Inc. • 03/18/2026 09:31:30 PM
- Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/18/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 09:06:45 PM
- Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology • GlobeNewswire Inc. • 01/26/2026 12:00:00 PM
- Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer • GlobeNewswire Inc. • 01/05/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 09:10:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 09:01:15 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 11/17/2025 09:22:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 12:20:47 PM
- Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/14/2025 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 10:29:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/05/2025 12:36:59 PM
- Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors • GlobeNewswire Inc. • 11/05/2025 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/04/2025 10:09:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/04/2025 10:03:27 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/04/2025 09:54:39 PM
- Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting • GlobeNewswire Inc. • 11/03/2025 02:15:00 PM
- Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program • GlobeNewswire Inc. • 10/06/2025 11:30:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2025 11:30:37 AM
- Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference • GlobeNewswire Inc. • 08/28/2025 12:00:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2025 11:16:20 AM

